Risedronic acid
- Generic Name
- Risedronic acid
- Brand Names
- Actonel, Atelvia
- Drug Type
- Small Molecule
- Chemical Formula
- C7H11NO7P2
- CAS Number
- 105462-24-6
- Unique Ingredient Identifier
- KM2Z91756Z
- Background
Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.
- Indication
Risedronic acid is indicated for the treatment of osteoperosis in men, treatment of Paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis.
- Associated Conditions
- Hypercalcemia of Malignancy, Osteoporosis, Paget’s Disease
- Associated Therapies
- -
VERtebral Fracture Treatment Comparisons in Osteoporotic Women
- Conditions
- Interventions
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1366
- Registration Number
- NCT01709110
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain
Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2012-08-29
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 1053
- Registration Number
- NCT01675297
- Locations
- 🇰🇷
Chung-ang university hospital, Seoul, Korea, Republic of
Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 31
- Registration Number
- NCT01611571
- Locations
- 🇺🇸
Columbia University Medical Center, Harkness Pavilion, New York City, New York, United States
IGF-1 and Bone Loss in Women With Anorexia Nervosa
- Conditions
- Interventions
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 148
- Registration Number
- NCT01406444
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover
- Conditions
- Interventions
- First Posted Date
- 2010-11-29
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 61
- Registration Number
- NCT01249261
- Locations
- 🇸🇪
Investigational Site, Goteborg, Sweden
Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2010-10-07
- Lead Sponsor
- University of Alberta
- Registration Number
- NCT01215890
- Locations
- 🇨🇦
Gastrointestinal and Liver Disease Research (GILDR) Group, Edmonton, Alberta, Canada
Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 684815
- Registration Number
- NCT01077817
A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture
- Conditions
- Interventions
- First Posted Date
- 2009-04-24
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 224
- Registration Number
- NCT00887354
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain
Antiepileptic Drugs and Osteoporotic Prevention Trial
- Conditions
- Interventions
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2015-07-24
- Lead Sponsor
- Boston VA Research Institute, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT00869622
- Locations
- 🇺🇸
VA Boston Healthcare System, Boston, Massachusetts, United States
Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-03-11
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 20
- Registration Number
- NCT00859703
- Locations
- 🇫🇷
Service de Rhumatology et de Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.